Peregrine Pharma (PPHM) Reports In-Line Q2 Loss

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q2 loss of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $2.83 million versus the consensus estimate of $2.28 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Ondas Holdings Inc. (ONDS) Misses Q2 EPS by 9c
• Pulmatrix (PULM) Reports Q2 Loss of $0.29
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance